BCRX — BioCryst Pharmaceuticals, Inc.
$7.61
$-0.07 (-0.91%)
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Market Cap
$1.96B
Forward P/E
8.9x
52-Week Range
N/A
BCRX Price History
Revenue vs. Net Income
$875M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$345M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
108.9%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.8x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.3%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+5.7%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
